In this video, Lou Basenese interviews Michael Heltzen about going IPO and the current challenges in SynBio - and how Invizyne can alleviate them - among other interesting topics, including the introduction of a paradigm shift in biomanufacturing.
“What does our technology do? We build biosolutions. Humankind has built a lot of things based on petrochemicals or things we have taken from nature and made into chemicals. We can make a new generation of that by re-engineering enzymes, putting them in a bioreactor, and making them produce all kind of chemicals that turns into products - like drugs, nutraceuticals, and all the way out to industrial chemicals like biofuels.” – states Michael Heltzen.
Forward-Looking Statements
This collateral contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.
